Increased secretion of Gas6 by smooth muscle cells in human atherosclerotic carotid plaques. 2012

Sylvain Clauser, and Olivier Meilhac, and Ivan Bièche, and Pierre Raynal, and Patrick Bruneval, and Jean-Baptiste Michel, and Delphine Borgel
EA 4531, Université Paris-Sud, Châtenay-Malabry, France. sylvain.clauser@apr.aphp.fr

Vitamin K-dependent protein Gas6 (growth-arrest specific gene 6) plays a role in vascular smooth muscle cell (VSMC) survival and migration, as well as in endothelium and leukocyte activation, and could therefore be involved in atherosclerosis. However, the study of mouse models has led to contradictory results regarding the pro- or anti-atherogenic properties of Gas6, and relatively few data are available in human pathophysiology. To better understand the implication of Gas6 in human atherosclerosis, we studied Gas6 expression and secretion in vitro in human VSMC, and analysed the effect of Gas6 on inflammatory gene expression in these cells. We show that Gas6 secretion in VSMC is strongly induced by the anti-inflammatory cytokine transforming growth factor (TGF)β, and that VSMC stimulation by recombinant Gas6 decreases the expression of inflammatory genes tumour necrosis factor (TNF)α and intracellular adhesion molecule (ICAM)-1. The study of Gas6 expression in human carotid endarterectomy samples revealed that Gas6 is mainly expressed by VSMC at all stages of human atherosclerosis, but is not detected in normal vessel wall. Analysis of plaque secretomes showed that Gas6 secretion is markedly higher in non-complicated plaques than in complicated plaques, and that TGFβ secretion pattern mirrors that of Gas6. We conclude that Gas6 is secreted in human atherosclerotic plaques by VSMC following stimulation by TGFβ, and that Gas6 secretion decreases with plaque complication. Therefore, we propose that Gas6 acts as a protective factor, in part by reducing the pro-inflammatory phenotype of VSMC.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents

Related Publications

Sylvain Clauser, and Olivier Meilhac, and Ivan Bièche, and Pierre Raynal, and Patrick Bruneval, and Jean-Baptiste Michel, and Delphine Borgel
October 1997, Circulation research,
Sylvain Clauser, and Olivier Meilhac, and Ivan Bièche, and Pierre Raynal, and Patrick Bruneval, and Jean-Baptiste Michel, and Delphine Borgel
April 2012, Angiology,
Sylvain Clauser, and Olivier Meilhac, and Ivan Bièche, and Pierre Raynal, and Patrick Bruneval, and Jean-Baptiste Michel, and Delphine Borgel
April 2016, Molecular imaging and biology,
Sylvain Clauser, and Olivier Meilhac, and Ivan Bièche, and Pierre Raynal, and Patrick Bruneval, and Jean-Baptiste Michel, and Delphine Borgel
March 1989, Differentiation; research in biological diversity,
Sylvain Clauser, and Olivier Meilhac, and Ivan Bièche, and Pierre Raynal, and Patrick Bruneval, and Jean-Baptiste Michel, and Delphine Borgel
August 1981, In vitro,
Sylvain Clauser, and Olivier Meilhac, and Ivan Bièche, and Pierre Raynal, and Patrick Bruneval, and Jean-Baptiste Michel, and Delphine Borgel
August 2006, Stroke,
Sylvain Clauser, and Olivier Meilhac, and Ivan Bièche, and Pierre Raynal, and Patrick Bruneval, and Jean-Baptiste Michel, and Delphine Borgel
June 1975, Biulleten' eksperimental'noi biologii i meditsiny,
Sylvain Clauser, and Olivier Meilhac, and Ivan Bièche, and Pierre Raynal, and Patrick Bruneval, and Jean-Baptiste Michel, and Delphine Borgel
May 1996, Cardiovascular research,
Sylvain Clauser, and Olivier Meilhac, and Ivan Bièche, and Pierre Raynal, and Patrick Bruneval, and Jean-Baptiste Michel, and Delphine Borgel
March 2011, International journal of clinical and experimental pathology,
Sylvain Clauser, and Olivier Meilhac, and Ivan Bièche, and Pierre Raynal, and Patrick Bruneval, and Jean-Baptiste Michel, and Delphine Borgel
December 2000, Atherosclerosis,
Copied contents to your clipboard!